Recent Updates
Recently added Catalysts
IMNM

Harnessing the Human Memory B Cell Response To Develop Antibody - Based Therapeutics

Key Takeaway: 25 Novel Insights from Discovery Engine 1. Adv Clin Chem. 2016;74:103 - 41.DOI: 10.1016/bs.acc.2015.12.005 2. Mol Cancer. 2019 Oct 23;18(1):146. doi : 10.1186/s12943 - 019 - 1074 - 3 3. Including some commercially - validated targets such as ERBB2 Provides Critical Insights Into
Price reaction · baseline $17.73 (2021-10-14 close) · hit after-hours · clean, no other IMNM news in the window
day 0 close · peak
-0.7%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+56%
120-day peak, hindsight
Typical move
1.9%
average across 2 past catalysts
Cash runway
~25 mo
Minimal dilution risk
Lead asset
177Lu-3050
Phase 1 · Solid Malignancies

Full Press Release Details

25 Novel Insights from Discovery Engine 1. Adv Clin Chem. 2016;74:103 - 41.DOI: 10.1016/bs.acc.2015.12.005 2. Mol Cancer. 2019 Oct 23;18(1):146. doi : 10.1186/s12943 - 019 - 1074 - 3 3. Including some commercially - validated targets such as ERBB2 Provides Critical Insights Into Cancer Biology Such As: Membrane dynamics Exosome control of the tumor microenvironment 1 - 2 Novel immune checkpoints that serve as functional, tumor - derived inhibitors of immunity CONFIDENTIAL - FOR INTERNAL USE ONLY Systematic Mining of Antibodies Reveal Disease Relevant Functional Clusters 300,000 HYBRIDOMAS 1,300 HITS >50 ANTIBODY / ANTIGEN PAIRS 3 A Highly Productive Platform Immune Modulation Novel Targets Discovery Engine Extracellular Matrix
Thank You Immunome, Inc. 665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | www.immunome.com
Last updated: Oct 15, 2021